|
gptkbp:instanceOf
|
anthelmintic drug
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
1970s
|
|
gptkbp:ATCCode
|
P02BA01
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
|
|
gptkbp:bioavailability
|
80%
|
|
gptkbp:brand
|
gptkb:Biltricide
gptkb:Cesol
gptkb:Distocide
gptkb:Cysticide
|
|
gptkbp:CASNumber
|
55268-74-1
|
|
gptkbp:category
|
antineoplastic agent
|
|
gptkbp:chemicalClass
|
isoquinoline-pyrazine derivative
|
|
gptkbp:contraindication
|
ocular cysticercosis
|
|
gptkbp:cost
|
inexpensive
|
|
gptkbp:discoveredBy
|
gptkb:Bayer
gptkb:Merck
|
|
gptkbp:eliminationHalfLife
|
0.8–1.5 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasMolecularFormula
|
C19H24N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Praziquantel
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
increases permeability of cell membranes to calcium ions
|
|
gptkbp:meltingPoint
|
136–138 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
80–85%
|
|
gptkbp:PubChem_CID
|
4719
4891
CHEMBL1433
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
dizziness
fatigue
headache
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:synonym
|
gptkb:PZQ
gptkb:Praziquantelum
gptkb:Praziquantelum_(INN)
|
|
gptkbp:UNII
|
KUF5VD7K2E
|
|
gptkbp:usedFor
|
treatment of schistosomiasis
treatment of tapeworm infections
treatment of liver flukes
|
|
gptkbp:usedIn
|
gptkb:veterinary_medicine
human medicine
|
|
gptkbp:bfsParent
|
gptkb:Tapeworm
|
|
gptkbp:bfsLayer
|
6
|